Continuous infusion of coagulation factors: Current opinion

Angelika Batorova, Uri Martinowitz*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


PURPOSE OF REVIEW: To review the most recent reports on continuous infusion of coagulation factors, focusing on the current issues relating to this mode of therapy. RECENT FINDINGS: Continuous infusion has been extensively used as an alternative to intermittent bolus factor replacement since the 1990s. To date, more than 100 reports comprising more than 800 continuous infusion treatments in various clinical situations have been published, with an increase in the current utilization of recombinant coagulation factors. An excellent hemostatic efficacy of continuous infusion has been reported. Continuous infusion protocols, however, still vary widely in terms of the different hemostatic levels targeted, dosage regimens, modes of continuous infusion and duration of therapy, which obviously result in variations in the cost-effectiveness reported by different centers. SUMMARY: Continuous infusion has been shown to be a safe and cost-effective mode of replacement for treatment of hemophilia. The lack of evidence-based information on the hemostatic levels to be maintained in specific clinical situations, and recent concerns regarding the development of inhibitors, particularly in patients with mild hemophilia treated with continuous infusion, need to be addressed by prospective, randomized studies that compare traditional intermittent injections and the continuous infusion mode of factor replacement.

Original languageEnglish
Pages (from-to)308-315
Number of pages8
JournalCurrent Opinion in Hematology
Issue number5
StatePublished - Sep 2006
Externally publishedYes


  • Coagulation factors
  • Continuous infusion
  • Recombinant factor VIII


Dive into the research topics of 'Continuous infusion of coagulation factors: Current opinion'. Together they form a unique fingerprint.

Cite this